No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
Coadministration of emtricitabine/tenofovir-DF and pyrazinamide alone has not been studied but based on metabolism and clearance a clinically significant interaction is unlikely. Pyrazinamide is mainly metabolized by xanthine oxidase. Coadministration of TB treatment containing pyrazinamide (with rifampicin, isoniazid and ethambutol) and emtricitabine/tenofovir-DF (with efavirenz) increased pyrazinamide Cmax by 14%. Emtricitabine AUC and Cmin increased by 5% and 26% and Cmax decreased by 3%. Tenofovir AUC and Cmin increased by 13% and 9% and Cmax decreased by 2%.